Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Acquisitions (2016 - 2018)

Myriad Genetics (MYGN) has disclosed Acquisitions for 4 consecutive years, with -$1.1 million as the latest value for Q4 2018.

  • On a quarterly basis, Acquisitions changed N/A to -$1.1 million in Q4 2018 year-over-year; TTM through Dec 2020 was -$1.1 million, a N/A change, with the full-year FY2022 number at $57.2 million, changed N/A from a year prior.
  • Acquisitions was -$1.1 million for Q4 2018 at Myriad Genetics, down from $279.6 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $279.6 million in Q3 2018 to a low of -$1.1 million in Q4 2018.
  • A 3-year average of $98.9 million and a median of $3.1 million in 2016 define the central range for Acquisitions.